CML-IN-1, also known as compound 7 and compound 4, is a potent anticancer agent that demonstrates a strong induced-apoptosis effect in the human chronic myeloid leukemia (CML) cell line K562. It diminishes protein phosphorylation within the PI3K/Akt signaling pathway to exert its effects and suppresses cell proliferation through the inhibition of the MEK/ERK signaling pathway in colorectal cancer [1] [2].

CML-IN-1（化合物7）在K562细胞中表现出较低的细胞毒性，具有较高的生物活性，IC 50值为0.038μM [1]。CML-IN-1（化合物4）显著降低了HCT116细胞的增殖率，其48小时和72小时的IC 50值分别为8.04 ± 0.94μM和5.52 ± 0.42μM [2]。此外，CML-IN-1（化合物4）呈剂量依赖性抑制HCT116细胞的集落形成、迁移和侵袭能力，并通过诱导细胞凋亡和G2/M期细胞周期阻滞发挥作用 [2]。它还能抑制HCT116细胞中MEK/ERK信号通路的活化 [2]。